Article
Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2009
Dezentjé Vincent O, Guchelaar Henk-Jan, Nortier Johan W R, van de Velde Cornelis J H, Gelderblom Hans
Abstract excerpt
In October 2006 the Food and Drug Administration recommended an update in the tamoxifen label to reflect the increased risk of recurrence in breast cancer patients who are cytochrome P450 2D6 (CYP2D6) poor metabolizers. This recommendation was based on only a few studies at that time. More clinical studies addressing the relation between the CYP2D6 genotype and tamoxifen efficacy have been published since, mostly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.